All In Biotech

Drug Trial Radar · NCT06598462

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study With an Extension to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis (ALAMERE)

Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 184 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

184

Actual

Start

Oct 16, 2024

Primary completion

Apr 30, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Uniquity One (UNI)Industry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.

Conditions

  • Eosinophilic Esophagitis (EoE)

Interventions

  • Solrikitug Low DoseBiological

    Solrikitug low dose subcutaneous injection

  • Solrikitug Mid DoseBiological

    Solrikitug mid dose subcutaneous injection

  • Solrikitug High DoseBiological

    Solrikitug high dose subcutaneous injection

  • PlaceboOther

    Placebo subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Histological response of peak esophageal eosinophil per HPF count of ≤6Time frame: Week 24
  2. Change from baseline in DSQ (Dysphagia Symptom Questionnaire) scoreTime frame: Week 24

Locations

73 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site 1039

    Dothan, Alabama

  • Research Site 1018

    Glendale, Arizona

  • Research Site 1018

    Peoria, Arizona

  • Research Site 1037

    Scottsdale, Arizona

  • Research Site 1003

    Tucson, Arizona

  • Research Site 1023

    Englewood, California

  • Research Site 1005

    Irvine, California

  • Research Site 1015

    San Diego, California

  • Research Site 1034

    Aurora, Colorado

  • Research Site 1027

    Cromwell, Connecticut

  • Research Site 1040

    Inverness, Florida

  • Research Site 1001

    Jacksonville, Florida

  • Research Site 1049

    Miami, Florida

  • Research Site 1007

    Boise, Idaho

  • Research Site 1048

    Glenview, Illinois

  • Research Site 1022

    Iowa City, Iowa

  • Research Site 1033

    Topeka, Kansas

  • Research Site 1032

    Chevy Chase, Maryland

  • Research Site 1004

    Boston, Massachusetts

  • Research Site 1024

    Ann Arbor, Michigan

  • Research Site 1013

    Wyoming, Michigan

  • Research Site 1006

    Plymouth, Minnesota

  • Research Site 1042

    Creve Coeur, Missouri

  • Research Site 1016

    Reno, Nevada

  • Research Site 1045

    Freehold, New Jersey

  • Research Site 1043

    Jackson, New Jersey

  • Research Site 1026

    Chapel Hill, North Carolina

  • Research Site 1021

    High Point, North Carolina

  • Research Site 1012

    Columbus, Ohio

  • Research Site 1020

    Harrisburg, Pennsylvania

  • Research Site 1030

    Philadelphia, Pennsylvania

  • Research Site 1014

    Dallas, Texas

  • Research Site 1008

    Houston, Texas

  • Research Site 1036

    Pearland, Texas

  • Research Site 1041

    Rockwell, Texas

  • Research Site 1002

    Ogden, Utah

  • Research Site 1019

    Salt Lake City, Utah

  • Research Site 1017

    Sandy City, Utah

  • Research Site 1111

    Maroochydore, Australia

  • Research Site 1107

    Woolloongabba, Australia

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.